Abstract
When designing a clinical trial, a number of design features including the sample size have to be decided upon. The sample size calculation usually requires some discussion of relevant effect sizes and information about nuisance parameters such as standard deviations or overall event rates, with nuisance parameters being estimated from previous studies. Using a novel endpoint or moving into a new indication, no or only very limited information might be available and the sample size calculation is therefore subject to considerable uncertainty. Internal pilot study designs that allow sample size reestimation midcourse of the ongoing study have been proposed to make trials more robust to misspecifications of nuisance parameters in the planning phase. In this article we present the design of a recently completed randomized active controlled trial in dermatology as a case study. Furthermore, we demonstrate how type I error rate control can be achieved when testing for noninferiority and explore operating characteristics such as power and sample size distributions through simulations motivated by the case study. Finally, relevant regulatory guidelines on sample size reestimation are referred to.
Similar content being viewed by others
References
Wittes J, Brittain E. The role of internal pilot studies in increasing the efficacy of clinical trials. Stat Med. 1990;9:65–72.
Bristol DR. Shurzinske L. Blinded sample size adjustment. Drug Inf J. 2001;35:1123–1130.
Friede T, Kieser M. Sample size recalculation in internal pilot study designs: a review (with discussion). Biometric J. 2006;48:537–555.
Friede T, Kieser M. Blinded sample size reassessment in non-inferiority and equivalence trials. Stat Med. 2003;22:995–1007.
Kieser M. Friede T. Re-calculating the sample size in internal pilot study designs with control of the type I error rate. Stat Med. 2000; 19:901–911.
ICH E9 Expert Working Group. Statistical principles for clinical trials: ICM Harmonized Tripartite Guideline. Stat Med. 1999;18:1905–1942.
Committee for Medicinal Products for Human Use. Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. 2007 CHMP/EWP/2459/02.
O’Neill RT. FDA’s draft guidance on adaptive designs in drug development: current status and issues. Presented at the 21st Annual DIA EuroMeeting. Berlin. 2009.
Committee for Medicinal Products for Human Use. Guideline on the choice of the non-inferiority margin. 2005. EMEA/CPMP/EWP/2158/99.
Hung HMJ, Wang SJ, O’Neill R. A regulatory perspective on choice of margin and statistical inference issues in non-inferiority trials. Biometric J. 2005;47:28–36.
Hung HMJ, Wang SJ, O’Neill R. Challenges and regulatory experiences with non-inferiority trial design without placebo arm. Biometric J. 2009;51:324–334.
Friede T, Kieser M. Sample size adjustment in clinical trials for proving equivalence. Drug Inf J. 2001;35:1401–1408.
Friede T, Mitchell C, Müller-Velten G. Blinded sample size reestimation in non-inferiority studies with binary endpoint. Biometric J. 2007; 49:903–916.
Chuang-Stein C, Anderson K, Gallo P, Collins S. Sample size reestimation: a review and recommendations. Drug Inf J. 2006;40:475–484.
Proschan MA. Sample size re-estimation in clinical trials. Biometric J. 2009;51:348–357.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Friede, T., Stammer, H. Blinded Sample Size Recalculation in Noninferiority Trials: A Case Study in Dermatology. Ther Innov Regul Sci 44, 599–607 (2010). https://doi.org/10.1177/009286151004400507
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286151004400507